Month: August 2023

Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome Strengthened the Board of Directors and Management Team with Multiple AppointmentsREDWOOD CITY, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update. “During our second quarter, we continued our preparations to begin a study in chronic spontaneous urticaria, which we anticipate initiating in the coming months,” said...

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023. “In the last year, we have successfully focused our resources to drive value across three main pillars: (1) moving our EB613 program along the right path to a Phase 3 registrational study, (2) developing a potential new generation for EB612 and (3) expanding our technological capabilities and platform. Our 2022 R&D plan resulted in pre-clinical validation of proprietary new generations of our oral peptide delivery platform. These are primarily designed to modify pharmacokinetic (PK)/ pharmacodynamic (PD) parameters, optimize bioavailability and...

Volcon ePowersports Reports Second Quarter 2023 Operational and Financial Results

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today reported its operational highlights and financial results for the second quarter of 2023. Company Highlights:As of June 30, 2023, we have 142 dealers Taken delivery of our first eight Stag validation units in 2023 that include our custom suspension parts in addition to the GM propulsion components and expect to launch the Stag to dealers in the fourth quarter of 2023 Have taken pre-orders for the Stag of more than $115 million of expected revenue if all orders are fulfilled1 Grunt EVO launch expected in the third quarter of 2023 and Runt LT launch expected in the fourth quarter of 2023The Company’s US dealer count has remained consistent with the count as of...

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

– Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 – Appointment of Kate McKinley as Chief Business Officer – Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 – Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association’s Scientific Sessions – Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics...

Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into early 2025 SEATTLE, Aug. 11, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Steady progress towards achieving key scientific and business milestones continued during the second quarter, highlighted by our VISTA-targeting KVA12123 clinical program,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “We are pleased with recruitment...

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. Board continues to evaluate strategic alternatives for the Company to maximize shareholder value BOULDER, Colo., Aug. 11, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Over the past few months, the Board and management have...

Correction: Grant of Incentive Subscription Rights in IDEX Biometrics 11 August 2022 *CORR

Written by Customer Service on August 11, 2023. Posted in Public Companies.

The board of directors of IDEX Biometrics ASA resolved on 11 August 2023 to issue 18,566,450 incentive subscription rights to 84 new and continuing employees and individual contractors in the IDEX Biometrics group. The grant was made under the company’s 2023 incentive subscription rights plan as resolved at the annual general meeting on 23 May 2023. The exercise price of the subscription rights is NOK 0.68 per share for 11,166,450 SRs, which SRs vest by 25% per year over four years, and NOK 0.15 per share for 7,400,000 SRs, which SRs vest by 50% per year over two years. The SRs expire on 23 May 2028. Following the grants there are 101,509,226 subscription rights outstanding in IDEX Biometrics. Primary insidersIDEX discloses transactions by the following primary insiders, who were granted incentive subscription rights (SRs) to IDEX...

Proposed changes to Maha’s board of directors and executive management

Written by Customer Service on August 11, 2023. Posted in Public Companies.

The nomination committee of Maha Energy AB (publ) (“Maha” or the “Company”) has informed the Company’s board of directors that it intends to propose that an extraordinary general meeting resolves to appoint Paulo Thiago Mendonça as the new chairman of the board of directors. The board of directors has therefore resolved to appoint Kjetil Solbraekke as the new CEO, effective as from the extraordinary general meeting electing Paulo Thiago Mendonça as the chairman of Maha’s board of directors. “The change we are proposing today is in line with our intention to governance Maha to future success. We are strengthening the execution of our management to operate our assets in order to pursue the creation of a cash flow-oriented company with a solid balance sheet and continue our growth strategy,” says Paulo Thiago Mendonça, CEO Maha, and Kjetil...

Nokia Corporation: Repurchase of own shares on 11.08.2023

Written by Customer Service on August 11, 2023. Posted in Public Companies.

Nokia CorporationStock Exchange Release11 August 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 11.08.2023 Espoo, Finland – On 11 August 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 336,953 3.55CEUX 44,189 3.55AQEU 2,188 3.53TQEX 6,670 3.57Total 390,000 3.55* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU)...

EURO Ressources reports earnings for the second quarter and six months ended June 30, 2023

Written by Customer Service on August 11, 2023. Posted in Earnings Releases And Operating Results.

NEWS RELEASE Paris: EUREURO RESSOURCES REPORTS EARNINGS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2023 Paris, France, August 11, 2023: EURO Ressources S.A. (“EURO” or “the Company”) (Paris: EUR) today announced its unaudited statutory interim financial results prepared in accordance with French Generally Accepted Accounting Principles (“GAAP”) and its unaudited condensed interim financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) for the six months ended June 30, 2023. These unaudited interim financial statements were approved by the Board of Directors on August 11, 2023. All financial amounts are expressed in Euros (“€” or “euros”) unless otherwise specified. Highlights Under French GAAP, EURO reported net earnings of €11.0 million (€0.177 per share) for the six months...

Month: August 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals